Erlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). Erlotinib HCl was approved. Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. For the signal to be transmitted, two EGFR molecules need to come together to form a homodimer. These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues, which generates phosphotyrosine residues, recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processes. When erlotinib binds to EGFR, formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.
EGFR Inhibitors Related Products:
Erlotinib hcl; Gefitinib; AG-490; Dacomitinib; WZ4002; Pelitinib; Brigatinib analog; Allitinib; Rociletinib; Varlitinib; Icotinib; WHI-P154; CNX-2006; AG-18; Nazartinib